Drug

Cilostazol

Regulatory activity · MHRA

Emerging researchLate-stage development

Also known as Pletal, Cilostazole, 3,4-dihydro-6-(4-(1-cyclohexyl-1H-tetrazol-5-yl)butoxy)-2(1H)-quinolinone, 6-(4-(1-cyclohexyl-1H-tetrazol-5-yl)butoxy)-3,4-dihydro-2(1H)-quinolinone+2 more

Pletal, Cilostazole, 3,4-dihydro-6-(4-(1-cyclohexyl-1H-tetrazol-5-yl)butoxy)-2(1H)-quinolinone, 6-(4-(1-cyclohexyl-1H-tetrazol-5-yl)butoxy)-3,4-dihydro-2(1H)-quinolinone, 6-(4-(1-cyclohexyl-1H-tetrazol-5-yl)butoxy)-3,4-dihydrocarbostyril, Cilostazolum.

RxNorm21107 ChEMBLCHEMBL799UNIIN7Z035406B

Research papers

Active clinical trials

Regulatory events

Latest activity

beta

Recent clinical, regulatory, research and industry developments relating to this drug.

Targeting Residual Activity By Precision, Biomarker-Guided Combination Therapies of Multiple Sclerosis (TRAP-MS)

Clinical trial2026-07-08Results expected Q1 2027 · ClinicalTrials.gov

CiLostAzol for pReventIon of Recurrent sTroke in Africa

Clinical trial2026-06-18Results expected Q3 2029 · ClinicalTrials.gov

Retinal Vasoreactivity is a Marker for Cerebral Small Vessel Disease Progression

Clinical trial2026-06-01Primary completion · ClinicalTrials.gov

Comparing Clopidogrel and Cilostazol in Type 2 Diabetes Patients With Carotid Atherosclerosis

Clinical trial2026-05-05Results expected Q4 2026 · ClinicalTrials.gov

The Effect and Safety of Therapy Adding Cilostazol in Acute Ischemic Stroke Due to Large Artery Atherosclerosis: CHANGE Trial

Clinical trial2026-03-27Results expected Q1 2028 · ClinicalTrials.gov

Ticagrelor Versus Cilostazol in Moderate and Moderate-to-severe Ischemic Stroke, a Randomized Controlled Trial

Clinical trial2025-11-30Primary completion · ClinicalTrials.gov

Evaluating the Safety and Efficacy of Cilostazol in the Treatment of Nonalcoholic Fatty Liver Disease Patients.

Clinical trial2025-11-25Results expected Q4 2026 · ClinicalTrials.gov

The Effect of Cilostazol on the Clinical Outcome of Patients with Parkinson's Disease

Clinical trial2025-10-01Primary completion · ClinicalTrials.gov

Prevention of Stroke Recurrence and Disease Progression in Cerebral Small Vessel Disease With Cilostazol: a Multicenter, Open-Label, Randomized Controlled Trial

Clinical trial2025-09-23Results expected Q3 2027 · ClinicalTrials.gov

Combining Aspirin With Ticagrelor or Cilostazol in Large-vessel Minor Stroke or TIA, a Randomized Controlled Trial

Clinical trial2025-09-19Primary completion · ClinicalTrials.gov

Drug Safety Update: Cilostazol (Pletal): risks of cardiovascular and bleeding events

Regulatory2014-12-11MHRA

Multicenter randomized trial evaluating the efficacy of cilostazol on ischemic vascular complications after drug-eluting stent implantation for coronary heart disease: results of the CILON-T (influence of CILostazol-based triple antiplatelet therapy ON ischemic complication after drug-eluting stenT implantation) trial.

Research2011-01-01Journal of the American College of Cardiology

Profile

Identifiers & mechanism

Canonical identifiers, marketed brand names and mechanism, resolved across RxNorm, ChEMBL and ATC.

Canonical name

Cilostazol

Aliases & brands

PletalCilostazole3,4-dihydro-6-(4-(1-cyclohexyl-1H-tetrazol-5-yl)butoxy)-2(1H)-quinolinone6-(4-(1-cyclohexyl-1H-tetrazol-5-yl)butoxy)-3,4-dihydro-2(1H)-quinolinone6-(4-(1-cyclohexyl-1H-tetrazol-5-yl)butoxy)-3,4-dihydrocarbostyrilCilostazolum

RxNorm CUI

21107

ChEMBL ID

CHEMBL799

UNII

N7Z035406B

Regulatory jurisdictions

mhra

Regulatory timeline

1 event

The complete regulatory record, grouped by authority — approvals, safety advisories and label changes. Each authority shows its most recent events; expand one to read its full history.

Authorities

MHRA

Total events

mhraMedicines and Healthcare products Regulatory Agency· 1 event

2014-12-11Safety communicationSafety

Drug Safety Update: Cilostazol (Pletal): risks of cardiovascular and bleeding events

Evidence ↗

Contains public sector information from the Medicines and Healthcare products Regulatory Agency (MHRA) licensed under the Open Government Licence (OGL v3).